304 related articles for article (PubMed ID: 27780603)
1. Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
Lim MS; Chapman K; Swanepoel P; Enjeti AK
Pathology; 2016 Dec; 48(7):712-719. PubMed ID: 27780603
[TBL] [Abstract][Full Text] [Related]
2. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
3. Interlaboratory variability in the measurement of direct oral anticoagulants: results from the external quality assessment scheme.
Tripodi A; Chantarangkul V; Legnani C; Testa S; Tosetto A
J Thromb Haemost; 2018 Mar; 16(3):565-570. PubMed ID: 29322630
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
5. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
[TBL] [Abstract][Full Text] [Related]
6. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
[TBL] [Abstract][Full Text] [Related]
7. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
8. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
11. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
McGrail R; Revsholm J; Nissen PH; Grove EL; Hvas AM
Thromb Res; 2016 Dec; 148():107-110. PubMed ID: 27835819
[TBL] [Abstract][Full Text] [Related]
12. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study.
Testa S; Legnani C; Tripodi A; Paoletti O; Pengo V; Abbate R; Bassi L; Carraro P; Cini M; Paniccia R; Poli D; Palareti G
J Thromb Haemost; 2016 Nov; 14(11):2194-2201. PubMed ID: 27566988
[TBL] [Abstract][Full Text] [Related]
13. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.
Ebner M; Birschmann I; Peter A; Spencer C; Härtig F; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Crit Care; 2017 Feb; 21(1):32. PubMed ID: 28196509
[TBL] [Abstract][Full Text] [Related]
14. Lupus-anticoagulant testing at NOAC trough levels.
Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
[TBL] [Abstract][Full Text] [Related]
15. PT, aPTT, TT and the hemostatic safety threshold of dabigatran and rivaroxaban.
Ibrahim F; Calmette L; Layka A; Horellou MH; Mazoyer É; Gouin-Thibault I; Flaujac C
Ann Biol Clin (Paris); 2016 Aug; 74(4):457-64. PubMed ID: 27492699
[TBL] [Abstract][Full Text] [Related]
16. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
Douxfils J; Chatelain B; Hjemdahl P; Devalet B; Sennesael AL; Wallemacq P; Rönquist-Nii Y; Pohanka A; Dogné JM; Mullier F
Thromb Res; 2015 May; 135(5):852-60. PubMed ID: 25743887
[TBL] [Abstract][Full Text] [Related]
17. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
18. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Platton S; Hunt C
Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
[TBL] [Abstract][Full Text] [Related]
19. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
[TBL] [Abstract][Full Text] [Related]
20. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples.
Bonar R; Favaloro EJ; Mohammed S; Ahuja M; Pasalic L; Sioufi J; Marsden K
Pathology; 2016 Jan; 48(1):60-71. PubMed ID: 27020211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
